NUK - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov NUK. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 223
1.
  • A randomized trial of bevac... A randomized trial of bevacizumab for newly diagnosed glioblastoma
    Gilbert, Mark R; Dignam, James J; Armstrong, Terri S ... New England journal of medicine/˜The œNew England journal of medicine, 02/2014, Letnik: 370, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized ...
Celotno besedilo

PDF
2.
  • Dose-dense temozolomide for... Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
    Gilbert, Mark R; Wang, Meihua; Aldape, Kenneth D ... Journal of clinical oncology, 11/2013, Letnik: 31, Številka: 32
    Journal Article
    Recenzirano
    Odprti dostop

    Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an ...
Celotno besedilo

PDF
3.
  • Neurologic complications of... Neurologic complications of immune checkpoint inhibitors
    Fellner, Avi; Makranz, Chen; Lotem, Michal ... Journal of neuro-oncology, 05/2018, Letnik: 137, Številka: 3
    Journal Article
    Recenzirano

    Immune checkpoint inhibitors (ICPIs) have recently emerged as a novel treatment for cancer. These agents, transforming the field of oncology, are not devoid of toxicity and cause immune-related side ...
Celotno besedilo
4.
  • Treatment with bevacizumab ... Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors
    Bokstein, Felix; Shpigel, Shulim; Blumenthal, Deborah T. Cancer, 15 May 2008, Letnik: 112, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    BACKGROUND Response rates to second‐line chemotherapy in recurrent high‐grade glial tumors are low and new effective treatments are needed. The objective of this study was to evaluate response rates ...
Celotno besedilo
5.
  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
    Mellinghoff, Ingo K; van den Bent, Martin J; Blumenthal, Deborah T ... The New England journal of medicine, 08/2023, Letnik: 389, Številka: 7
    Journal Article
    Recenzirano

    Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 ...
Preverite dostopnost
6.
  • Pembrolizumab: first experi... Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
    Blumenthal, Deborah T.; Yalon, Michal; Vainer, Gilad W. ... Journal of neuro-oncology, 09/2016, Letnik: 129, Številka: 3
    Journal Article
    Recenzirano

    Patients with progressive primary brain tumors (PBT) are attracted to promising new treatments, even prior to convincing data. Anti-PD1 immunotherapies have been in the spotlight since publication of ...
Celotno besedilo
7.
  • Is more better? The impact ... Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
    Blumenthal, Deborah T; Gorlia, Thierry; Gilbert, Mark R ... Neuro-oncology, 08/2017, Letnik: 19, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This regimen has been adopted with ...
Celotno besedilo

PDF
8.
  • MRI radiomics analysis of m... MRI radiomics analysis of molecular alterations in low-grade gliomas
    Shofty, Ben; Artzi, Moran; Ben Bashat, Dafna ... International journal for computer assisted radiology and surgery, 04/2018, Letnik: 13, Številka: 4
    Journal Article
    Recenzirano

    Purpose Low-grade gliomas (LGG) are classified into three distinct groups based on their IDH1 mutation and 1p/19q codeletion status, each of which is associated with a different clinical expression. ...
Celotno besedilo
9.
  • Differentiation between vas... Differentiation between vasogenic edema and infiltrative tumor in patients with high‐grade gliomas using texture patch‐based analysis
    Artzi, Moran; Liberman, Gilad; Blumenthal, Deborah T. ... Journal of magnetic resonance imaging, September 2018, Letnik: 48, Številka: 3
    Journal Article
    Recenzirano

    Background High‐grade gliomas (HGGs) induce both vasogenic edema and extensive infiltration of tumor cells, both of which present with similar appearance on conventional MRI. Using current ...
Celotno besedilo
10.
  • An independently validated ... An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
    Gittleman, Haley; Lim, Daniel; Kattan, Michael W ... Neuro-oncology, 05/2017, Letnik: 19, Številka: 5
    Journal Article
    Recenzirano
    Odprti dostop

    Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a ...
Celotno besedilo

PDF
1 2 3 4 5
zadetkov: 223

Nalaganje filtrov